{"id":61195,"date":"2026-03-25T12:20:53","date_gmt":"2026-03-25T04:20:53","guid":{"rendered":"https:\/\/flcube.com\/?p=61195"},"modified":"2026-03-25T12:20:54","modified_gmt":"2026-03-25T04:20:54","slug":"kelun-biotechs-skb103-wins-nmpa-approval-novel-taa-pd-l1-bispecific-adc-enters-clinical-trials-for-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61195","title":{"rendered":"Kelun\u2011Biotech’s SKB103 Wins NMPA Approval \u2013 Novel TAA\u2011PD\u2011L1 Bispecific ADC Enters Clinical Trials for Advanced Solid Tumors"},"content":{"rendered":"\n

Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd.<\/strong> (HKG: 6990<\/a>) announced that its SKB103<\/strong>, a novel TAA\u2011PD\u2011L1 bispecific antibody\u2011drug conjugate (ADC)<\/strong>, has received NMPA clinical trial approval<\/strong> for advanced solid tumors<\/strong> \u2013 positioning the potential best\u2011in\u2011class<\/strong> candidate developed on Kelun\u2011Biotech’s proprietary OptiDC platform<\/strong> at the forefront of next\u2011generation cancer immunotherapy.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>SKB103 \u2013 TAA\u2011PD\u2011L1 bispecific ADC<\/td><\/tr>
Company<\/strong><\/td>Sichuan Kelun\u2011Biotech Biopharmaceutical Co., Ltd. (HKG: 6990)<\/td><\/tr>
Development Platform<\/strong><\/td>OptiDC<\/strong> \u2013 proprietary ADC platform<\/td><\/tr>
Indication<\/strong><\/td>Advanced solid tumors<\/td><\/tr>
Approval Type<\/strong><\/td>Clinical trial approval (IND)<\/td><\/tr>
Global Positioning<\/strong><\/td>Potential best\u2011in\u2011class<\/strong> bispecific ADC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile \u2013 Dual\u2011Mechanism Innovation<\/h2>\n\n\n\n
Feature<\/th>SKB103 Design<\/th>Therapeutic Advantage<\/th><\/tr><\/thead>
Structure<\/strong><\/td>Single\u2011molecule bispecific ADC<\/strong><\/td>Simplified manufacturing vs. dual\u2011component combinations<\/td><\/tr>
Dual Targets<\/strong><\/td>TAA (tumor\u2011associated antigen)<\/strong> + PD\u2011L1<\/strong><\/td>Tumor\u2011targeted payload delivery + immune checkpoint modulation<\/td><\/tr>
Dual Mechanism<\/strong><\/td>Cytotoxic payload delivery<\/strong> + tumor immune microenvironment modulation<\/strong><\/td>Enhanced anti\u2011tumor efficacy; potential for immunogenic cell death<\/td><\/tr>
Platform Origin<\/strong><\/td>OptiDC<\/strong> \u2013 Kelun\u2011Biotech proprietary ADC platform<\/td>Validated linker\u2011payload technology; optimized DAR (drug\u2011to\u2011antibody ratio)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Preclinical Evidence<\/h2>\n\n\n\n
Parameter<\/th>Result<\/th>Clinical Implication<\/th><\/tr><\/thead>
Anti\u2011tumor Activity<\/strong><\/td>Excellent<\/strong> across multiple solid tumor models<\/td>Broad spectrum potential; indication\u2011agnostic initial development<\/td><\/tr>
Safety Profile<\/strong><\/td>Favorable<\/strong><\/td>Supports clinical dose escalation; manageable therapeutic window<\/td><\/tr>
Mechanism Validation<\/strong><\/td>Simultaneous TAA\u2011mediated targeting + PD\u2011L1 immune modulation<\/td>Novel biology; potential for superior efficacy vs. monospecific ADCs or PD\u20111\/PD\u2011L1 inhibitors alone<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Competitive Positioning<\/h2>\n\n\n\n
Dimension<\/th>Current ADC\/IO Landscape<\/th>SKB103 Differentiation<\/th><\/tr><\/thead>
Monospecific ADCs<\/strong><\/td>Targeted payload delivery only (e.g., Enhertu, Trodelvy)<\/td>Added immune modulation<\/strong> \u2013 potential for sustained anti\u2011tumor immunity<\/td><\/tr>
PD\u20111\/PD\u2011L1 Inhibitors<\/strong><\/td>Immune checkpoint blockade alone<\/td>Added cytotoxic payload<\/strong> \u2013 direct tumor cell killing; potential for cold\u2011to\u2011hot tumor conversion<\/td><\/tr>
Combination Approaches<\/strong><\/td>ADC + IO sequential or concurrent administration<\/td>Single\u2011molecule bispecific<\/strong> \u2013 simplified pharmacokinetics; reduced combination toxicity; manufacturing efficiency<\/td><\/tr>
Bispecific ADC Pipeline<\/strong><\/td>Limited competitors (e.g., AstraZeneca, BioNTech early\u2011stage programs)<\/td>First\u2011to\u2011clinical potential<\/strong> in TAA\u2011PD\u2011L1 bispecific ADC class<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n